<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486378</url>
  </required_header>
  <id_info>
    <org_study_id>BNT122-01</org_study_id>
    <secondary_id>2020-000451-12</secondary_id>
    <secondary_id>U1111-1250-5294</secondary_id>
    <nct_id>NCT04486378</nct_id>
  </id_info>
  <brief_title>A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer</brief_title>
  <official_title>A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioNTech SE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of&#xD;
      RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive,&#xD;
      surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>DFS defined as the time from randomization to occurrence of any of the following events, whichever occurs first:&#xD;
Locoregional recurrence or distant metastases as determined by an independent central radiology assessment.&#xD;
Occurrence of second primary (same or other) cancer as determined by an independent central radiology assessment.&#xD;
Death from any cause.&#xD;
Loss to follow-up is censored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>RFS is defined as the time from randomization to occurrence of any of the following events, whichever occurs first:&#xD;
Locoregional recurrence or distant metastases as determined by the investigator.&#xD;
Death from any cause.&#xD;
Occurrence of second primary (same or other) cancer as determined by the investigator is ignored.&#xD;
Loss to follow-up is censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence (TTR)</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>TTR is defined as the time from randomization to occurrence of any of the following events (i.e., events related to the same cancer), whichever occurs first:&#xD;
Locoregional recurrence or distant metastases as determined by the investigator.&#xD;
Death from same cancer.&#xD;
Occurrence of second primary (same or other) cancer as determined by the investigator is ignored.&#xD;
Loss to follow-up and deaths from other cancer, non-cancer-related deaths, treatment-related deaths are censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>TTF is defined as the time from randomization to occurrence of any of the following events, whichever occurs first:&#xD;
Locoregional recurrence or distant metastases as determined by the investigator.&#xD;
Occurrence of second primary (same or other) cancer as determined by the investigator.&#xD;
Death from any cause except non-cancer related death.&#xD;
Loss to follow-up and non-cancer-related deaths are censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>OS defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Circulating tumor DNA (ctDNA) status (every 3 months)</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment emergent adverse event (TEAE)</measure>
    <time_frame>15 months</time_frame>
    <description>TEAE, including Grade 3+, serious, fatal TEAE by relationship (AEs graded according to the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events, version 5.0 [CTCAE v5.0])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of dose reduction and discontinuation of IMP due to a TEAE.</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Colorectal Cancer Stage II</condition>
  <condition>Colorectal Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>RO7198457</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a recommended dose of RO7198457.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Observational group will undergo watchful waiting, which is the standard of care in this setting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7198457 intravenous (i.v.)</intervention_name>
    <description>RO7198457 administered as an IV infusion at protocol-specified intervals over 12 months.</description>
    <arm_group_label>Biomarker Cohort</arm_group_label>
    <arm_group_label>Exploratory Cohort</arm_group_label>
    <arm_group_label>RO7198457</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational group (no intervention)</intervention_name>
    <description>watchful waiting</description>
    <arm_group_label>Observational Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be a man or woman of at least 18 years of age.&#xD;
&#xD;
          -  Patients must have Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III&#xD;
             colon cancer per AJCC 2017 that has been surgically totally resected (R0 confirmed by&#xD;
             pathology report). Stage II (high risk) colon cancer is defined as Stage II disease&#xD;
             with any of the following risk factors for recurrence:&#xD;
&#xD;
               -  T4&#xD;
&#xD;
               -  Grade ≥ 3.&#xD;
&#xD;
               -  Clinical presentation with bowel obstruction or perforation.&#xD;
&#xD;
               -  Histological signs of vascular, lymphatic or perineural invasion.&#xD;
&#xD;
               -  &lt; 12 nodes examined.&#xD;
&#xD;
          -  Patients must have detectable ctDNA prior to start of adjuvant chemotherapy (AdCTx)&#xD;
             (except for the Biomarker Cohort).&#xD;
&#xD;
             • ctDNA assay must be performed through this study or study BNT000-001 ctDNA screening&#xD;
             protocol.&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of&#xD;
             0-1.&#xD;
&#xD;
          -  Patients must have adequate hematologic and organ function.&#xD;
&#xD;
          -  Adequate tumor material in formalin-fixed paraffin embedded (FFPE) blocks or as&#xD;
             sectioned tissue (only upon approval by sponsor) must be available (as described in&#xD;
             the laboratory manual).&#xD;
&#xD;
          -  The patient has started a standard of care AdCTx within 8 weeks post-surgery and has&#xD;
             completed at least 3 months of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness.&#xD;
&#xD;
          -  Diagnosed microsatellite instability (MSI) high tumors.&#xD;
&#xD;
          -  Prior therapy with any of the following:&#xD;
&#xD;
               -  Neo-adjuvant (radio)chemotherapy prior to surgery.&#xD;
&#xD;
               -  Treatment with systemic immunosuppressive medication within 2 weeks prior to&#xD;
                  initiation of trial treatment or anticipation of need for systemic&#xD;
                  immunosuppressive medication during trial treatment, with the exception of low&#xD;
                  dose steroids defined as 10 mg oral prednisone (or equivalent).&#xD;
&#xD;
               -  Current or recent (within the 28 days prior to randomization) treatment with&#xD;
                  another investigational drug.&#xD;
&#xD;
          -  Toxicities from previous anti-cancer therapies that have not resolved to baseline&#xD;
             levels or to Grade 1 or less except for alopecia and peripheral neuropathy.&#xD;
&#xD;
          -  Patients who developed metastatic disease.&#xD;
&#xD;
          -  Patients with known past or current malignancy other than inclusion diagnosis, except&#xD;
             for:&#xD;
&#xD;
               -  Cervical carcinoma of Stage 1B or less.&#xD;
&#xD;
               -  Non-invasive basal cell or squamous cell skin carcinoma.&#xD;
&#xD;
               -  Non-invasive, superficial bladder cancer.&#xD;
&#xD;
               -  Prostate cancer with a current PSA level &lt; 0.1 ng/mL.&#xD;
&#xD;
               -  Any curable cancer with a complete response (CR) of &gt; 2 years duration.&#xD;
&#xD;
          -  Patients with known allergies, hypersensitivity, or intolerance to RO7198457 or its&#xD;
             excipients.&#xD;
&#xD;
          -  Patients who had major surgery (e.g., surgery requiring general anesthesia) within 4&#xD;
             weeks before screening, or will not have fully recovered from surgery, or have surgery&#xD;
             planned during the time the patient are expected to participate in the trial.&#xD;
&#xD;
          -  Patients with active hepatitis B or C.&#xD;
&#xD;
          -  Patients who have a history of human immunodeficiency virus (HIV) antibody positivity,&#xD;
             or tests positive for HIV at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BioNTech Responsible Person</last_name>
    <role>Study Director</role>
    <affiliation>BioNTech SE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BioNTech clinical trials patient information</last_name>
    <phone>+49 6131 9084</phone>
    <phone_ext>1919</phone_ext>
    <email>patients@biontech.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BioNTech clinical trial information desk</last_name>
    <phone>+49 6131 9084</phone>
    <phone_ext>0</phone_ext>
    <email>info@biontech.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marin Cancer Care</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of Decatur, Cancer Care Specialists of IL</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon (Tennessee Oncology - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VZW Algemeen Ziekenhuis AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GHDC (Grand Hopital de Charleroi)</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centres Hospitaliers Jolimont</name>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum St. Josef-Hospital Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF)</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Praxis GmbH</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig AoeR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prosper Hospital</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruna</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Clinic Hematolo/Oncologia- ICMHO, Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>8041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HMN Sanchinarro, Centro Integral Oncologico Clara Campal (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Orense</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques De Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario De Santiago De Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

